Practice Changers in Advanced Prostate Cancer from ASCO 2017: STAMPEDE, LATITUDE vis-à-vis CHAARTED

Prostate cancer update: practice-changing data?Подробнее

LATITUDE study: major results in metastatic prostate cancerПодробнее

Key Trials on Advanced Prostate Cancer from ASCO GU 2017Подробнее

STAMPEDE trial changes standard of care | Nicholas JamesПодробнее

ASCO 2017: Ask The Prostate Cancer ExpertsПодробнее

ASCO 2017: Expert discussion on the latest in prostate cancerПодробнее

ASCO 2017: Following the practice changing results from STAMPEDEПодробнее

Practice Changers in Advanced Prostate Cancer from ASCO 2017: STAMPEDE, LATITUDE vis-à-vis CHAARTEDПодробнее

Recent trials in advanced prostate cancer: STAMPEDE and AdRadПодробнее

Results of the LATITUDE Trial in High-Risk Metastatic Hormone-Naive Prostate CancerПодробнее

Prostate Cancer Highlights from ASCO 2017 - Dr. Igor MorbeckПодробнее

LATITUDE: combination therapy for newly diagnosed prostate cancerПодробнее

STAMPEDE Will 'Change Practice' in High-Risk Prostate Cancer - Medpage TodayПодробнее

Sieber on CHAARTED for Advanced Prostate CancerПодробнее

STAMPEDE: Abiraterone results (Short version)Подробнее

Dr. Zhang Discusses the Impact of the STAMPEDE Trial in Prostate CancerПодробнее

Dr. Agarwal on the STAMPEDE and LATITUDE Trials for Prostate CancerПодробнее

Prostate Cancer Highlights from ASCO 2017 - Dr. Fernando VidigalПодробнее

Abiraterone: a step forward in the treatment of prostate cancerПодробнее